Barclays raised the firm’s price target on Boston Scientific (BSX) to $133 from $125 and keeps an Overweight rating on the shares. The company reported a Q2 beat on strong growth in Watchman and Farapulse, the analyst tells investors in a research note. The firm increased estimates post the report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific Reports Strong Q2 2025 Results
- Boston Scientific Reports Strong Q2 Growth Amid Challenges
- Boston Scientific’s Strong Financial Performance and Positive Outlook Earns Buy Rating
- Boston Scientific’s Strong Performance and Growth Potential Reinforce Buy Rating
- Boston Scientific price target raised to $127 from $124 at BTIG